Welcome to our dedicated page for Akero Therapeutics SEC filings (Ticker: AKRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing efruxifermin (EFX) for metabolic dysfunction-associated steatohepatitis (MASH) and related metabolic liver diseases. These regulatory documents offer detailed insight into Akero’s clinical programs, financial position, risk factors and corporate transactions.
Through its annual reports on Form 10-K and quarterly reports on Form 10-Q, Akero describes its business focus on serious metabolic diseases, outlines the design and objectives of the Phase 3 SYNCHRONY program, and discusses prior Phase 2b HARMONY and SYMMETRY results. Management’s discussion and analysis sections explain research and development spending, including costs associated with large global trials and manufacturing of clinical supplies for potential marketing applications.
Current reports on Form 8-K highlight material events. For example, Akero has filed an 8-K describing its Agreement and Plan of Merger with Novo Nordisk A/S and a wholly owned subsidiary of Novo Nordisk, under which Akero is expected to become a wholly owned subsidiary following stockholder approval and satisfaction of closing conditions. Another 8-K details the voluntary prepayment and termination of a prior loan agreement, providing context on changes in the company’s capital structure and debt obligations. Additional 8-K filings furnish quarterly earnings press releases and other significant updates.
Investors researching insider activity can review Forms 4 referenced in Akero’s proxy materials, which report changes in beneficial ownership by directors and executive officers. When available, proxy statements and related solicitation materials explain executive compensation, governance matters and, in connection with the proposed merger, information relevant to the stockholder vote. Stock Titan’s platform surfaces these filings as they are posted to EDGAR and adds AI-powered summaries to help readers interpret lengthy documents such as 10-Ks, 10-Qs, 8-Ks and proxy statements without having to parse every page manually.
Akero Therapeutics insider transactions on 09/02/2025 show Jonathan Young, Chief Operating Officer, exercised stock options and sold an equal number of shares under a Rule 10b5-1 plan. The filing reports an exercise/acquisition of 12,500 shares at $21.10 and sales totaling 12,500 shares executed at weighted-average prices of $45.776, $47.136 and $47.58. After these transactions Mr. Young beneficially owned 197,484 shares direct and additionally has three irrevocable trusts holding 20,000 shares each, which he disclaims as beneficial ownership. The transactions were effected pursuant to a 10b5-1 trading plan dated April 29, 2025.
Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics (AKRO), reported a securities transaction dated 08/15/2025. The filing shows an acquisition of 2,600 shares/options with a reported price of $19.62, increasing the reporting person’s beneficial ownership to 26,351 shares following the transaction.
The filing also discloses a derivative position: a stock option with a $19.62 exercise price covering 20,384 underlying common shares, of which 17,784 derivative securities are reported as beneficially owned. The option vests 25% on April 29, 2025, with the balance vesting in 36 equal monthly installments, subject to continued service. The form is signed by an attorney-in-fact on 08/19/2025.
Janus Henderson Group plc reported beneficial ownership of 6,738,556 ordinary shares of Akero Therapeutics, representing 8.5% of the class, and disclosed shared voting and dispositive power over those shares while reporting no sole voting or dispositive power.
The filing also states that JHIUS may be deemed the beneficial owner of 6,654,976 shares (8.4%) and identifies JHIUS, JHIUKL and JHIAIFML as indirect subsidiaries that are registered investment advisers advising Managed Portfolios. Janus Henderson certifies these holdings are held in the ordinary course of business and were not acquired to change or influence control.
RTW Investments, LP and Roderick Wong reported beneficial ownership of 5,873,308 shares of Akero Therapeutics, representing 7.3% of the outstanding common stock. The ownership is reported as shared voting and shared dispositive power, with no sole voting or dispositive power recorded.
The percentage is calculated using 79,717,570 shares outstanding as reported by the company. The filing is an amendment to a Schedule 13G and discloses that the RTW Funds hold the right to receive dividends or sale proceeds on the reported shares.
Jonathan Young, Chief Operating Officer of Akero Therapeutics (AKRO), filed a Form 4 reporting transactions dated 08/12/2025. The filing shows transactions effected pursuant to a Rule 10b5-1 trading plan dated April 29, 2025. The report records an acquisition of 12,500 common shares (and concomitant acquisition of 12,500 stock option rights with an exercise/conversion price of $21.10) and two sales totaling 12,500 shares sold at weighted-average prices of $47.721 and $48.324, respectively.
Following the reported activity the filing lists 197,484 shares beneficially owned directly and derivative holdings of 69,982 option-related instruments. The filing discloses three irrevocable trusts each holding 20,000 shares for the benefit of the reporting person’s children and states the reporting person disclaims beneficial ownership of those trust shares. The option referenced vests in 48 equal monthly installments commencing December 8, 2021.
Akero Therapeutics insider sale by CEO and director Andrew Cheng. The Form 4 reports that Mr. Cheng, who serves as President and CEO and is a company director, executed sales of common stock on 08/11/2025 pursuant to a Rule 10b5-1 trading plan dated August 16, 2024. The filing lists three dispositions of 10,795, 18,805 and 400 shares, each shown as sales, with weighted-average price ranges disclosed in the footnotes.
The footnotes state the shares were sold in multiple transactions at prices ranging $47.40–$48.39, $48.41–$49.39, and $49.43–$49.44, respectively. The report also shows the amount of common stock beneficially owned following the reported transactions as 509,962, 491,157 and 490,757 shares on the corresponding lines. The Form 4 is signed by an attorney-in-fact and identifies the trades as executed under the 10b5-1 plan; no other financial or operational data is included.
Jane Henderson, a director of Akero Therapeutics (AKRO), reported insider transactions dated 08/12/2025 showing linked non-derivative and derivative activity. The filing shows an acquisition of 3,000 common shares associated with a stock option having a conversion/exercise price of $7.009, and a sale of 3,000 common shares at $47.457. Following the reported transactions the filing shows she beneficially owned 9,398 shares of common stock directly. The disclosure also states that the related options are vested and currently exercisable.
Akero Therapeutics (AKRO) submitted a Form 144 reporting the proposed sale of 50,000 shares of common stock via J.P. Morgan Securities LLC on NASDAQ, with an aggregate market value reported as $2,414,000 and approximately 79,988,975 shares outstanding. The filing shows the shares were acquired by a stock option exercise and the acquisition date, payment date and approximate sale date are all listed as 08/12/2025, with payment in cash.
The form discloses no securities sold in the past three months and includes the seller’s representation about not possessing undisclosed material adverse information. Several issuer/filer identification fields in the provided content are blank, so the filing text here omits the named filer and named person for whose account the securities are to be sold.
Akero Therapeutics Form 144 filed for an insider sale of common stock. The notice reports an intended sale of 3,000 common shares with an aggregate market value of $142,371.90 from a total of 79,988,975 shares outstanding. The sale is listed for 08/12/2025 on NASDAQ through Morgan Stanley Smith Barney LLC.
The filing shows the securities were acquired and exercised on 08/12/2025 via a stock option exercise and paid in cash. It also states "Nothing to Report" for any securities sold during the past three months and includes the standard representation that the seller is not aware of any undisclosed material adverse information.
Schedule 13G/A disclosure: Wellington Management Group LLP and related Wellington entities report beneficial ownership of 3,409,946 shares of Akero Therapeutics common stock, representing 4.28% of the class. The filing shows shared voting power of 2,924,691 shares and shared dispositive power of 3,409,946, with no sole voting or dispositive power. The securities are owned of record by clients of Wellington’s investment advisers rather than by Wellington itself.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, consistent with a passive, institutional ownership disclosure under Schedule 13G/A.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
